Comparing the efficacy and renal safety of metformin and imeglimin in diabetic rats

Charang Ngammoiran; Thongam Ramananda Singh; Laishram Elizabeth Devi; L. Tarinita Devi; Usham Dharmaraja Meetei

doi:10.18203/2320-6012.ijrms20253967

Authors

Charang Ngammoiran Department of Pharmacology, Regional Institute of Medical Sciences, Imphal, Manipur, India
Thongam Ramananda Singh Department of Pharmacology, Regional Institute of Medical Sciences, Imphal, Manipur, India
Laishram Elizabeth Devi Department of Pharmacology, Shija Academy of Health Sciences, Imphal, Manipur, India
L. Tarinita Devi Department of Pharmacology, Regional Institute of Medical Sciences, Imphal, Manipur, India
Usham Dharmaraja Meetei Department of Pharmacology, Regional Institute of Medical Sciences, Imphal, Manipur, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20253967

Keywords:

Diabetes mellitus, Metformin, Imeglimin, Glycemic control, Diabetic kidney disease, Renal safety

Abstract

Background: Diabetic kidney disease (DKD) represents a significant cause of end-stage kidney disease and is closely linked to substantially higher rates of cardiovascular morbidity and mortality. As a result, there is a need for therapies that can prevent DKD, improve patient compliance, reduce side effects, and be cost-effective.

Methods: Healthy male albino rats (150-200 g) were screened, and hyperglycemia was induced in 24 rats, and after one week, hyperglycemia was confirmed. The rats were then divided into four groups (Groups 1, 2, 3, and 4) (n=6). Group 1 was designated as diabetic control group, while nephrotoxicity was induced in the remaining rats. Group 1 and Group 2 (toxic control group) were treated with vehicle. Group 3 (metformin group) was treated with metformin, and Group 4 (imeglimin group) received imeglimin, both at a dose of 180 mg/kg/day for two weeks.

Results: On day 21, there was a significant reduction in serum urea and creatinine levels in Group 3 (p<0.05 and p<0.05, respectively) and Group 4 (p<0.001 and p<0.001, respectively) when compared with Group 1. Also, both Groups 3 and 4 showed a significant reduction in serum urea (p<0.001, p<0.001) and creatinine (p<0.001, p<0.001) levels when compared with Group 2. However, the glycemic control by imeglimin did not significantly differ from that of metformin on day 21.

Conclusions: Imeglimin was more effective in improving renal function parameters, demonstrating greater renal safety compared to metformin.

Metrics

Metrics Loading ...

References

Forouhi NG, Wareham NJ. Epidemiology of diabetes. Medicine (Abingdon). 2014;42(12):698-702. DOI: https://doi.org/10.1016/j.mpmed.2014.09.007

Powers AC, Fowler MJ, Rickels MR. Diabetes Mellitus: Management and therapies. In: Loscalzo J, Kasper DL, Longo DL, Fauci AS, Hauser SL, Jameson JL, editors. Harrison's principles of internal medicine. 21st ed. New York: McGraw Hill Education; 2022: 3104-3119.

International Diabetes Federation. Diabetes facts and figures. Brussels, Belgium: IDF Diabetes Atlas 10th ed; 2021. Available at: www.diabetesatlas.org. Accessed on 17 March 2023.

Hallakou-Bozec S, Vial G, Kergoat M, Fouqueray P, Bolze S, Borel A, et al. Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes. Diabetes Obes Metab. 2021;23(3):664-73. DOI: https://doi.org/10.1111/dom.14277

Mimura I, Chen Z, Natarajan R. Epigenetic alterations and memory: key players in the development/progression of chronic kidney disease promoted by acute kidney injury and diabetes. Kidney Int. 2025;107(3):434-56. DOI: https://doi.org/10.1016/j.kint.2024.10.031

Selby NM, Taal MW. An updated overview of diabetic nephropathy: diagnosis, prognosis, treatment goals and latest guidelines. Diabetes Obes Metab. 2020;22(S1):3-15. DOI: https://doi.org/10.1111/dom.14007

Yamazaki T, Mimura I, Tanaka T, Nangaku M. Treatment of Diabetic Kidney Disease: Current and Future. Diabetes Metab J. 2021;45(1):11-26. DOI: https://doi.org/10.4093/dmj.2020.0217

Kikkawa R, Koya D, Haneda M. Progression of diabetic nephropathy. Am J Kidney Dis. 2003;41(3 Suppl 1):S19-21. DOI: https://doi.org/10.1053/ajkd.2003.50077

Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP- activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108(8):1167-74. DOI: https://doi.org/10.1172/JCI200113505

Xu J, Liu L, Xu L, Xing Y, Ye S. Metformin alleviates renal injury in diabetic rats by inducing Sirt1/FoxO1 autophagic signal axis. Clin Exp Pharmacol Physiol. 2020;47(4):599-608. DOI: https://doi.org/10.1111/1440-1681.13226

Hallakou-Bozec S, Kergoat M, Moller DE, Bolze S. Imeglimin preserves islet β-cell mass in Type 2 diabetic ZDF rats. Endocrinol Diabetes Metab. 2020;4(2):e00193. DOI: https://doi.org/10.1002/edm2.193

Yaribeygi H, Maleki M, Sathyapalan T, Jamialahmadi T, Sahebkar A. Molecular mechanisms by which imeglimin improves glucose homeostasis. J Diabetes Res. 2020;2020:8768954. DOI: https://doi.org/10.1155/2020/8768954

Mima A. Safety and Efficacy of Imeglimin for Type 2 Diabetes in Patients Undergoing Dialysis. In Vivo. 2023;37(3):1334-8. DOI: https://doi.org/10.21873/invivo.13214

Wang Z, Yang Y, Xiang X, Zhu Y, Men J, He M. Estimation of the normal range of blood glucose in rats. Wei Sheng Yan Jiu. 2010;39(2):133-42.

Thammitiyagodage MG, de Silva NR, Rathnayake C, Karunakaran R, WGSS K, Gunatillka MM, et al. Biochemical and histopathological changes in wistar rats after consumption of boiled and un-boiled water from high and low disease prevalent areas for chronic kidney disease of unknown etiology (CKDu) in north Central Province (NCP) and its comparison with low disease prevalent Colombo, Sri Lanka. BMC Nephrol. 2020;21(38):1-12. DOI: https://doi.org/10.1186/s12882-020-1693-3

Shirwaikar A, Punitha ISR, Upadhye M, Dhiman A. Antidiabetic activity of alcohol root extract of Holostemma annulare in NIDDM Rats. Pharm Biol. 2007;45(6):440-5. DOI: https://doi.org/10.1080/13880200701388989

Singh P, Srivastava MM, Khemani LD. Renoprotective effects of Andrographis paniculata (Burm. f.) Nees in rats. Ups J Med Sci. 2009;114(3):136-9. DOI: https://doi.org/10.1080/03009730903174321

Ghosh MN. Fundamentals of experimental pharmacology. 7th ed. Kolkata: Hilton and Company; 2019.

Herling AW, Maas J, Seeger K. Techniques of blood collection in laboratory animals. In: Vogel HG, Scholkens BA, Sandow J, Vogel WH, Muller G, editors. Drug discovery and evaluation. 2nd ed. Germany: Springer; 2002: 1371-1374.

Taskiran E, Erbas O, Yigitturk G, Meral A, Akar H, Taskiran D. Exogenously administered adenosine attenuates renal damage in streptozotocin-induced diabetic rats. Ren Fail. 2016;38(8):1276-82. DOI: https://doi.org/10.1080/0886022X.2016.1207054

Nasiri AR, Karamibonari AR. Protective effects of Melissa officinalis L. extract on gentamicin-induced renal failure in diabetic rats. Med Lab J. 2023;17(1):35-41. DOI: https://doi.org/10.61186/mlj.17.1.35

Madhag Z, Al-Isawi Z. Empagliflozin alone and in combination with metformin mitigates diabetes-associated renal complications. J Med Life. 2024;17(5):530-5. DOI: https://doi.org/10.25122/jml-2023-0301

Mohammad HMF, Galal Gouda S, Eladl MA, Elkazaz AY, Elbayoumi KS, Farag NE, et al. Metformin suppresses LRG1 and TGFβ1/ALK1-induced angiogenesis and protects against ultrastructural changes in rat diabetic nephropathy. Biomed Pharmacother. 2023;158:114128. DOI: https://doi.org/10.1016/j.biopha.2022.114128

Uto A, Ishinoda Y, Asaga T, Tanahashi Y, Kobayashi A, Meshino H, et al. Imeglimin for Type 2 Diabetes Mellitus: Its Efficacy and Insight Into the Potential Benefit for Renal and Liver Function. Cureus. 2024;16(8):e66322. DOI: https://doi.org/10.7759/cureus.66322

Lachaux M, Soulié M, Hamzaoui M, Bailly A, Nicol L, Rémy‐Jouet I, et al. Short-and long-term administration of imeglimin counters cardiorenal dysfunction in a rat model of metabolic syndrome. Endocrinol Diabetes Metab. 2020;3(3):e00128. DOI: https://doi.org/10.1002/edm2.128

Pirags V, Lebovitz H, Fouqueray P. Imeglimin, a novel oral antidiabetic glimin, exhibits a good efficacy and safety profile in type 2 diabetic patients. Diabetes Obes Metab. 2012;14(9):852-8. DOI: https://doi.org/10.1111/j.1463-1326.2012.01611.x

Fouqueray P, Leverve X, Fontaine E, Baquié M, Wollheim C, Lebovitz H, et al. Imeglimin - A New Oral Anti-Diabetic that Targets the Three Key Defects of Type 2 Diabetes. J Diabetes Metab. 2011;2(4):1-8. DOI: https://doi.org/10.4172/2155-6156.1000126

Nishiyama K, Ono M, Tsuno T, Inoue R, Fukunaka A, Okuyama T, et al. Protective Effects of Imeglimin and Metformin Combination Therapy on β-Cells in db/db Male Mice. Endocrinology. 2023;164(8):bqad095. DOI: https://doi.org/10.1210/endocr/bqad095

Usui R, Hamamoto Y, Imura M, Omori Y, Yamazaki Y, Kuwata H, et al. Differential effects of imeglimin and metformin on insulin and incretin secretion-An exploratory randomized controlled trial. Diabetes Obes Metab. 2024;27(2):856-65. DOI: https://doi.org/10.1111/dom.16086